Article info

Download PDFPDF
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis

Authors

  1. Correspondence to:
    Mr E N van Roon
    Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR Leeuwarden, Netherlands; e.n.van.roonznb.nl
View Full Text

Citation

van Roon EN, Jansen TLTA, van de Laar MAFJ, et al
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis

Publication history

  • Accepted August 12, 2004
  • First published September 2, 2004.
Online issue publication 
January 09, 2022

Article Versions